US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. December 07, 2023

    Generics Price-Fixing Cases Should Stay In MDL, Judge Says

    The Pennsylvania federal judge overseeing sprawling multidistrict litigation against generic-drug makers on Thursday told the U.S. Judicial Panel on Multidistrict Litigation that she does not recommend transferring state enforcer actions out of the MDL yet, saying there's more the court can do to get the cases ready for trial or to tee up settlement talks.

  2. November 02, 2023

    States Want Generic Drug Price-Fixing Claims Back In Conn.

    State enforcers accusing several generic drugmakers of price-fixing asked the Judicial Panel on Multidistrict Litigation to move their case back to Connecticut federal court, saying legislation signed by President Joe Biden last year spares state enforcers from the MDL process.

  3. October 04, 2023

    States Back Off Bid To Block Sandoz Spinoff In Antitrust Case

    Novartis AG completed the planned spinoff of its Sandoz unit on Wednesday, after state enforcers and others withdrew their bid to block the move over concerns about recovering alleged overcharges from a sprawling conspiracy to fix generic drug prices.

  4. September 29, 2023

    States Ask To Block Sandoz Spinoff Over Price-Fixing Claims

    State enforcers and others have asked a Pennsylvania federal court to halt Novartis AG's planned spinoff of its Sandoz unit, saying the move could stop them from recovering overcharges from the company for a sprawling conspiracy to fix generic drug prices.

  5. August 17, 2023

    DOJ Wants Equal Access To Docs in Ex-Exec's Criminal Case

    The U.S. Department of Justice has urged a Pennsylvania federal judge to deny a former Taro Pharmaceutical executive's bid to use material from multidistrict litigation over alleged generic drug price-fixing to defend himself in a related criminal case, arguing the request would create an unfair advantage since the court previously rejected a similar ask from the government.

  6. May 23, 2023

    DOJ, Drug Buyers Rip Teva's Criminal Probe Doc Bid In MDL

    The government and drug buyers fired back in separate filings in Pennsylvania federal court Tuesday against Teva's bid to use material from a criminal investigation into alleged generic drug price-fixing to defend itself in parallel civil multidistrict litigation over similar allegations, arguing it would undermine prosecutions and create a procedural "mess."

  7. March 20, 2023

    DOJ Defends Ask For Docs From Drug Price-Fixing MDL

    The U.S. Department of Justice defended its bid for discovery materials from multidistrict litigation over generic drug price-fixing claims for use in the government's related criminal prosecutions, rejecting the pharmaceutical companies' claims that the DOJ wanted "unfettered access."

  8. March 13, 2023

    Pharma Cos. Say Civil Evidence Off Limits In Criminal Case

    Pharmaceutical companies that have been facing multidistrict litigation over price-fixing claims are saying absolutely not to an attempt by the U.S. Department of Justice to access civil discovery materials for use in criminal prosecutions tied to the alleged scheme.

  9. March 10, 2023

    Generic Drug Buyers Get $75M In Price-Fixing Deals Approved

    A Pennsylvania federal court signed off on settlements ending price-fixing claims from direct purchasers against Sun Pharmaceutical Industries Inc. and Taro Pharmaceutical Industries USA Inc. in ongoing multidistrict litigation over generic drug prices.

  10. February 27, 2023

    Drugmakers To Face Price-Fixing Claims From State AGs

    In a slew of rulings on Monday, a Pennsylvania federal court rejected most bids from drug companies seeking to nix sweeping price-fixing conspiracy allegations from a group of state attorneys general.